Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 3/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.33 |
| ▸ | HTR3B | O95264 | 2/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492160 | 0.91 | CHRNA7 (0.49) | CHRNA7GLAHTR3AHTR3EHTR3B | |
| SCHEMBL6487460 | 0.88 | CHRNA7 (0.41) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6493072 | 0.87 | CHRNA7 (0.33) | CHRNA7GLAHTR3AHTR3EHTR3B | |
| SCHEMBL6489157 | 0.86 | CHRNA7 (0.35) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6491600 | 0.85 | CHRNA7 (0.33) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6479577 | 0.84 | CHRNA7 (0.34) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6479251 | 0.84 | CHRNA7 (0.34) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6492732 | 0.81 | CHRNA7 (0.50) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6489366 | 0.80 | CHRNA7 (0.42) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL14608827 | 0.80 | CHRNA7 (0.42) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894042-B2 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-17 | — | — | US | claimed |
| EP-1476448-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | claimed |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | claimed |
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | claimed |
| WO-2003070731-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | claimed |
| US-6894042-B2 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1476448-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | disclosed |
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003070731-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | CHRNA7 2449/4885GLA 1275/4885HTR3A 4302/4885 |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | CHRNA7 2449/4885GLA 1275/4885HTR3A 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.